Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference
Esperion (NASDAQ: ESPR) ha annunciato la sua partecipazione alla prossima 24ª Conferenza Virtuale sulla Salute di Needham, programmata per il 7 aprile 2025, alle 8:45 ET. L'evento sarà accessibile tramite webcast sul sito web di Esperion, con una registrazione disponibile per circa 90 giorni.
Esperion è un'azienda biofarmaceutica in fase commerciale, nota per aver sviluppato l'unico farmaco orale, approvato dalla FDA, non statinico, da assumere una volta al giorno per i pazienti con LDL-C elevato e rischio di malattie cardiovascolari. I loro farmaci sono supportati dallo studio CLEAR sugli esiti cardiovascolari, che ha coinvolto quasi 14.000 pazienti.
L'azienda sta avanzando nel suo programma di nuova generazione che si concentra sugli inibitori dell'ATP citrato liasi (ACLYi), sfruttando nuove intuizioni sulla struttura e sulla funzione per un design razionale del farmaco. Esperion continua a espandersi a livello globale attraverso l'esecuzione commerciale, le partnership internazionali e lo sviluppo di pipeline precliniche.
Esperion (NASDAQ: ESPR) ha anunciado su participación en la próxima 24ª Conferencia Virtual de Salud de Needham, programada para el 7 de abril de 2025, a las 8:45 a.m. ET. El evento será accesible a través de un webcast en el sitio web de Esperion, con una repetición disponible durante aproximadamente 90 días.
Esperion es una empresa biofarmacéutica en etapa comercial, conocida por desarrollar el único medicamento oral, aprobado por la FDA, no estatínico, que se toma una vez al día para pacientes con LDL-C elevado y riesgo de enfermedad cardiovascular. Sus medicamentos están respaldados por el estudio CLEAR de resultados cardiovasculares, que involucró a casi 14,000 pacientes.
La empresa está avanzando en su programa de próxima generación centrado en los inhibidores de la ATP citrato liasa (ACLYi), aprovechando nuevos conocimientos sobre la estructura y función para un diseño racional de medicamentos. Esperion continúa expandiéndose a nivel global a través de la ejecución comercial, asociaciones internacionales y el desarrollo de su pipeline preclínico.
Esperion (NASDAQ: ESPR)는 2025년 4월 7일 오전 8시 45분 ET에 예정된 제24회 니드햄 가상 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 Esperion의 웹사이트를 통해 웹캐스트로 접근할 수 있으며, 약 90일 동안 다시 볼 수 있는 서비스도 제공됩니다.
Esperion은 LDL-C 수치가 높고 심혈관 질환 위험이 있는 환자를 위한 FDA 승인 경구용 비스타틴 약물을 개발한 상업 단계의 생명공학 회사입니다. 이들의 약물은 거의 14,000명의 환자가 참여한 CLEAR 심혈관 결과 시험에 의해 뒷받침됩니다.
회사는 구조와 기능에 대한 새로운 통찰력을 활용하여 합리적인 약물 설계를 위한 ATP 시트르산 리아제 억제제(ACLYi)에 초점을 맞춘 차세대 프로그램을 진행하고 있습니다. Esperion은 상업적 실행, 국제 파트너십 및 전임상 파이프라인 개발을 통해 글로벌로 계속 확장하고 있습니다.
Esperion (NASDAQ: ESPR) a annoncé sa participation à la prochaine 24e Conférence Virtuelle de Soins de Santé de Needham, prévue pour le 7 avril 2025 à 8h45 ET. L'événement sera accessible par webdiffusion via le site web d'Esperion, avec une rediffusion disponible pendant environ 90 jours.
Esperion est une entreprise biopharmaceutique en phase commerciale, connue pour avoir développé le seul médicament oral, approuvé par la FDA, non statinique, à prendre une fois par jour pour les patients présentant un LDL-C élevé et un risque de maladie cardiovasculaire. Leurs médicaments sont soutenus par l'étude CLEAR sur les résultats cardiovasculaires, impliquant près de 14 000 patients.
L'entreprise fait progresser son programme de nouvelle génération axé sur les inhibiteurs de l'ATP citrate lyase (ACLYi), tirant parti de nouvelles connaissances sur la structure et la fonction pour une conception rationnelle des médicaments. Esperion continue de s'étendre à l'échelle mondiale grâce à l'exécution commerciale, aux partenariats internationaux et au développement de pipelines précliniques.
Esperion (NASDAQ: ESPR) hat seine Teilnahme an der bevorstehenden 24. jährlichen Needham Virtual Healthcare Conference angekündigt, die für den 7. April 2025 um 8:45 Uhr ET geplant ist. Die Veranstaltung wird über ein Webcast auf der Website von Esperion zugänglich sein, mit einer Wiederholung, die etwa 90 Tage verfügbar sein wird.
Esperion ist ein biopharmazeutisches Unternehmen in der Kommerzialisierungsphase, das bekannt dafür ist, das einzige von der FDA zugelassene orale, einmal täglich einzunehmende nicht-statinische Medikament für Patienten mit erhöhtem LDL-C und Risiko für Herz-Kreislauf-Erkrankungen zu entwickeln. Ihre Medikamente werden durch die CLEAR Cardiovascular Outcomes Trial unterstützt, an der fast 14.000 Patienten teilnahmen.
Das Unternehmen entwickelt sein Programm der nächsten Generation, das sich auf ATP-Citrat-Lyase-Inhibitoren (ACLYi) konzentriert und neue Erkenntnisse über Struktur und Funktion für ein rationales Arzneimitteldesign nutzt. Esperion setzt seine globale Expansion durch kommerzielle Ausführung, internationale Partnerschaften und die Entwicklung von präklinischen Pipelines fort.
- None.
- None.
ANN ARBOR, Mich., March 24, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, at 8:45 a.m. ET.
The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
When is Esperion (ESPR) presenting at the Needham Healthcare Conference 2025?
How long will Esperion's (ESPR) Needham Conference webcast be available for replay?
What are the key products that Esperion (ESPR) is currently commercializing?
How many patients were involved in Esperion's (ESPR) CLEAR Cardiovascular Outcomes Trial?
What is Esperion's (ESPR) next-generation drug development program focused on?
